Refine
Document Type
- Article (2)
- Doctoral Thesis (1)
Language
- English (3)
Has Fulltext
- yes (3) (remove)
Is part of the Bibliography
- no (3) (remove)
Keywords
- Transcription (3) (remove)
Institute
Simple Summary:
CDK9, in combination with Cyclin T1, is one of the major regulators of RNA Polymerase II mediated productive transcription of critical genes in any cell. The activity of CDK9 is significantly up-regulated in a wide variety of cancer entities, to aid in the overexpression of genes responsible for the regulation of functions, which are beneficial to the cancer cells, like proliferation, survival, cell cycle regulation, DNA damage repair and metastasis. Enhanced CDK9 activity, therefore, leads to poorer prognosis in many cancer types, offering the rationale to target it using small-molecule inhibitors. Several, increasingly specific inhibitors, have been developed, some of which are presently in clinical trials. Other approaches being tested involve combining inhibitors against CDK9 activity with those against CDK9’s upstream regulators like BRD4, SEC and HSP90; or downstream effectors like cMYC and MCL-1. The inhibition of CDK9’s activity holds the potential to be a highly effective anti-cancer therapeutic.
Abstract:
Cyclin Dependent Kinase 9 (CDK9) is one of the most important transcription regulatory members of the CDK family. In conjunction with its main cyclin partner—Cyclin T1, it forms the Positive Transcription Elongation Factor b (P-TEFb) whose primary function in eukaryotic cells is to mediate the positive transcription elongation of nascent mRNA strands, by phosphorylating the S2 residues of the YSPTSPS tandem repeats at the C-terminus domain (CTD) of RNA Polymerase II (RNAP II). To aid in this process, P-TEFb also simultaneously phosphorylates and inactivates a number of negative transcription regulators like 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) Sensitivity-Inducing Factor (DSIF) and Negative Elongation Factor (NELF). Significantly enhanced activity of CDK9 is observed in multiple cancer types, which is universally associated with significantly shortened Overall Survival (OS) of the patients. In these cancer types, CDK9 regulates a plethora of cellular functions including proliferation, survival, cell cycle regulation, DNA damage repair and metastasis. Due to the extremely critical role of CDK9 in cancer cells, inhibiting its functions has been the subject of intense research, resulting the development of multiple, increasingly specific small-molecule inhibitors, some of which are presently in clinical trials. The search for newer generation CDK9 inhibitors with higher specificity and lower potential toxicities and suitable combination therapies continues. In fact, the Phase I clinical trials of the latest, highly specific CDK9 inhibitor BAY1251152, against different solid tumors have shown good anti-tumor and on-target activities and pharmacokinetics, combined with manageable safety profile while the phase I and II clinical trials of another inhibitor AT-7519 have been undertaken or are undergoing. To enhance the effectiveness and target diversity and reduce potential drug-resistance, the future of CDK9 inhibition would likely involve combining CDK9 inhibitors with inhibitors like those against BRD4, SEC, MYC, MCL-1 and HSP90.
5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) is an established pharmacological activator of AMP-activated protein kinase (AMPK). Both, AICAR and AMPK were reported to attenuate inflammation. However, AICAR is known for many AMPK-independent effects, although the mechanisms remain incompletely understood. Here we report a potent suppression of lipopolysaccharide (LPS)-induced inflammatory gene expression by AICAR in primary human macrophages, which occurred independently of its conversion to AMPK-activating 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl monophosphate. Although AICAR did not interfere with activation of cytosolic signalling cascades and nuclear translocation of nuclear factor - κB (NFκB) by LPS, it prevented the recruitment of NFκB and RNA polymerase II to target gene promoters. AICAR also inhibited signal transducer and activator of transcription 3 (STAT3)-dependent induction of interleukin (IL) IL-6 and IL-10 targets, while leaving STAT6 and HIF1α-dependent gene expression in IL-4 and dimethyloxalylgylcine-treated macrophages intact. This points to a transcription factor-specific mode of action. Attenuated gene expression correlated with impaired NFκB and STAT3, but not HIF-binding in electrophoretic mobility shift assays in vitro. Conclusively, AICAR interferes with DNA binding of NFκB and STAT3 to modulate inflammatory responses.
Compared to all other organisms with 1 to 3 heat stress transcription factors (Hsfs) or Hsf-related factors, plants have extraordinarily large Hsf families with more than 20 Hsfs. Plant Hsfs are classified into three classes according to their oligomerization domains which is built of hydrophobic heptad repeats (HR) in two parts, HR-A and HR-B. Both parts may be immediately adjacent (class B), or they are separated by insertion of 21 (class A) and 7 amino acid residues (class C). In plant Hsf family, detailed investigations are so far limited to Hsfs A1a, A2, A3, A4d, A9, and B1. They strongly indicate functional diversification to be the main reason for the coexistence of multiple Hsfs. As an example the functional triad of HsfA1a, HsfA2, and HsfB1 is essential for all three phases of the hs response, (i) the triggering of the response by HsfA1a as master regulator, (ii) the maintenance and high efficiency of hs gene transcription by cooperation of HsfA1a with Hsfs A2 and B1, and finally, (iii) the restoration of house-keeping gene transcription during the recovery phase mediated by HsfB1 in cooperation with house-keeping transcription factors. The results presented in this thesis for Hsfs A4 and A5 open completely different aspects of functional diversification and cooperation of Hsfs. HsfA4 and HsfA5 homooligomerize and bind to corresponding HSE motifs. But in contrast to the highly active HsfA4, HsfA5 is completely inactive as transcriptional activator. Yeast two hybrid and GST pull-down techniques showed that both Hsfs have strong tendency for heterooligomerization. Using fluorescence microscopy the HsfA4/A5 heterooligomers were found to localize in the nucleus. These complexes are transcriptionally inactive due to the impairment of DNA binding. The repressor function of HsfA5 requires only its OD and no additional factors, e.g. a putative co-repressor recruited by the C-terminal domain, are involved. Evidently, the repressor effect mainly results from the interference with the oligomeric state of HsfA4b, which is essential for efficient DNA binding and activator functions. EST database search revealed that plants have a single HsfA5 and usually two A4-type Hsfs. Using bioinformatics tools, Hsfs A4 and A5 were found to be phylogenetically closely related and clearly distinct from the other members of the Hsf family. On the basis of RT-PCR and Microarray data the representatives of the A4/A5 group are well expressed in different plant tissues albeit at very different levels which change with the developmental stages and stress conditions In rice and Arabidopsis, HsfA4 functions as an anti-apoptotic factor for stress induced oxidative damages. Based on my results, I hypothesize that HsfA5 functions as a novel type of selective repressor, regulating the function of A4-type Hsfs in plants. Considering the high sequence conservation with in plant Hsf family, it is tempting to speculate that this role of Hsf4/A5 pair is a fundamental feature of the Hsf system in plants.